Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Amortization of Deferred Charges (2022 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $468000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 2.9% to $468000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 23.22% decrease, with the full-year FY2025 number at $1.6 million, down 23.22% from a year prior.
  • Amortization of Deferred Charges was $468000.0 for Q4 2025 at Madrigal Pharmaceuticals, up from $329000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $753000.0 in Q4 2023 to a low of $178000.0 in Q2 2022.
  • A 4-year average of $460266.7 and a median of $468000.0 in 2025 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: soared 211.24% in 2023, then crashed 35.99% in 2024.
  • Madrigal Pharmaceuticals' Amortization of Deferred Charges stood at $306000.0 in 2022, then surged by 146.08% to $753000.0 in 2023, then plummeted by 35.99% to $482000.0 in 2024, then dropped by 2.9% to $468000.0 in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Amortization of Deferred Charges are $468000.0 (Q4 2025), $329000.0 (Q3 2025), and $371000.0 (Q2 2025).